TABLE VI -.
Cost of management of the acute episode of iTTP
| Resource used | Unit cost | PEX and immunosuppression | Caplacizumab + PEX and immunosuppression | ||
|---|---|---|---|---|---|
| Frequency | Total cost | Frequency | Total cost | ||
| Intensive care (days) | €1,108.00 (36) | 2.7 (16.33) | €2,991.60 | 1.34 (16.33) | €1,484.72 |
| Hospitalisation (days) | €384.11 (37) | 8.1 (16.33) | €3,111.29 | 8.2 (16.33) | €3,149.70 |
| Daily plasmapheresis (days) | €438.99 (38) | 6.5 (16.33) | €2,853.44 | 5.5 (16.33) | €2,414.45 |
| Additional plasmapheresis (days) | €438.99 (38) | 0.1 (16.33) | €43.90 | 0.1 (16.33) | €43.90 |
| ADAMTS13 test | €78.90 (39) | 4.0* | €315.60 | 4.0* | €315.60 |
| Haematology specialist visit | €20.66 (38) | 2.0* | €41.32 | 2.0* | €41.32 |
| Treatment with folic acid 5 mg daily during plasmapheresis | €0.09 (40) | 0.3 (34) | €0.03 | 0.3 (34) | €0.02 |
| Immunosuppressive therapy | €35.54 (41) | 3.0 (34) | €106.62 | 3.0 (34) | €106.62 |
| Total cost | €9,463.79 | €7,556.33 | |||
*The test is performed four times during the acute episode of iTTP. Two of the four tests are usually performed when the patient has already been discharged from the hospital, then they are performed during a specialist visit by the haematologist.